Rasagiline added to dopamine agonist has small benefit in Parkinson’s

From Clinical Neurology News, 25 June 2013: Rasagiline is safe and efficacious as add-on therapy in patients with early Parkinson’s disease whose symptoms are not adequately controlled with dopamine agonist monotherapy, results from a randomized, double-blind placebo-controlled study suggest. Data from the ANDANTE study showed that adding rasagiline (1 mg/day) to dopamine agonist therapy led Continue reading Rasagiline added to dopamine agonist has small benefit in Parkinson’s

Dopamine agonist withdrawal syndrome frequency determined prospectively

From Clinical Neurology News, 24 June 2013: Nearly one-quarter of patients decreasing or stopping dopamine agonist therapy experience dopamine agonist withdrawal syndrome, and one third of those suffer severe symptoms, according to results from the EuroDaws study. In the prospective, observational study of 51 patients with Parkinson’s disease who were withdrawn from dopamine agonist treatment, Continue reading Dopamine agonist withdrawal syndrome frequency determined prospectively